Skip to main content

ResMed Opens Manufacturing Centre in Singapore, Expanding Manufacturing Footprint to Support Growth, Development, and Production of Digital Health Solutions

Written by Customer Service on . Posted in Public Companies.

ResMed Tuas Facility Ribbon Cutting

From to left to right: Brendan Mullins, Vice President of Manufacturing, ResMed; William Hodgman, Australian High Commissioner to Singapore; Jonathan Kaplan, United States Ambassador to Singapore; Peter Farrell, Chairman, ResMed; Mick Farrell, Chief Executive Officer, ResMed; Mr Tharman Shanmugaratnam, Senior Minister, Singapore; Tan Kong Hwee, Executive Vice President, Economic Development Board; Rob Douglas, President and Chief Operating Officer, ResMed; Andrew Price, President of Global Operations, ResMed; Naji Chalhoub, Vice President of Manufacturing, ResMed.
From to left to right: Brendan Mullins, Vice President of Manufacturing, ResMed; William Hodgman, Australian High Commissioner to Singapore; Jonathan Kaplan, United States Ambassador to Singapore; Peter Farrell, Chairman, ResMed; Mick Farrell, Chief Executive Officer, ResMed; Mr Tharman Shanmugaratnam, Senior Minister, Singapore; Tan Kong Hwee, Executive Vice President, Economic Development Board; Rob Douglas, President and Chief Operating Officer, ResMed; Andrew Price, President of Global Operations, ResMed; Naji Chalhoub, Vice President of Manufacturing, ResMed.

ResMed Tuas Advanced Manufacturing Centre – Front View

ResMed Tuas Advanced Manufacturing Centre - Front View
ResMed Tuas Advanced Manufacturing Centre – Front View

ResMed Tuas Advanced Manufacturing Centre – Rear View

ResMed Tuas Advanced Manufacturing Centre - Rear View
ResMed Tuas Advanced Manufacturing Centre – Rear View
  • New 270,000-square-foot (25,000-square-meter) facility in Tuas marks the next stage in ResMed’s more than decade-long presence in Singapore; will account for nearly 1,000 jobs across a variety of skill sets, contributing to the country’s fast-growing local health technology sector
  • The facility significantly increases ResMed’s production capacity of masks for its cloud-connected medical devices and serves as the primary production location for its newest AirSense 11 device

SINGAPORE, Nov. 17, 2022 (GLOBE NEWSWIRE) — ResMed this week celebrated the grand opening of its new Advanced Manufacturing Centre in Tuas, Singapore.

The 270,000-square-foot (25,000-square-meter) facility more than doubles the size of ResMed’s footprint in Singapore and serves as ResMed’s key manufacturing hub in Asia-Pacific. The facility will account for nearly 1,000 jobs and features smart dashboards that integrates real-time data to monitor the performance of production lines.

The facility has the manufacturing capacity and footprint to scale production for connected devices and mask systems to help people sleep, breathe, and live better lives – particularly people worldwide with sleep apnea, a chronic disease affecting an estimated 936 million people worldwide – including nearly 2.3 million people in Singapore, according to Lancet Respiratory Medicine. ResMed’s AirSense 11, the company’s latest PAP (positive airway pressure) device that allows users to monitor their own sleep apnea treatment via the myAir app, will be produced in this facility.

“Singapore’s strategic location and support for business investment, coupled with ResMed’s world-leading devices and digital health offerings, provides the perfect opportunity to expand our manufacturing capabilities while supporting local jobs and the region’s economy,” said ResMed CEO Mick Farrell. “The opening of this facility supports the continued growth of ResMed’s product portfolio to meet the needs of millions of people across Singapore, Asia-Pacific, and the world.”

ResMed has been operating in Singapore for over a decade, and will continue to grow regional teams across manufacturing, product development, operations, corporate, and commercial functions.

ResMed’s grand opening of its Advanced Manufacturing Centre was officiated by guest of honour and Singapore Senior Minister Tharman Shanmugaratnam, along with Australia’s High Commissioner to Singapore William Hodgman and U.S. Ambassador to Singapore Jonathan Kaplan.

“This facility marks a major milestone for ResMed, both in your growth as a world-leading medical device company, and in the expansion of your footprint in Singapore. I am glad ResMed has chosen Singapore as your partner in innovation and growth,” said Senior Minister Tharman Shanmugaratnam.

For more information on ResMed, please visit http://www.resmed.sg.

About ResMed
At ResMed we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

For media
Natasha Vijaya
+65 8189 6299
resmedsg@allisonpr.com   

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/82923e7f-6af9-4ca2-a0f2-16ec7129dccd

https://www.globenewswire.com/NewsRoom/AttachmentNg/065a3101-07ac-467a-b5bc-0b0204ae76f4

https://www.globenewswire.com/NewsRoom/AttachmentNg/d4ea3b9e-7eba-4a81-a162-342e9c052488

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.